Skip to Content
Merck

Phenytoin for neuropathic pain and fibromyalgia in adults.

The Cochrane database of systematic reviews (2012-05-18)
Fraser Birse, Sheena Derry, R Andrew Moore
ABSTRACT

Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. Phenytoin is an established antiepileptic drug that has been used occasionally to treat intractable trigeminal neuralgia. To assess the analgesic efficacy and adverse effects of the antiepileptic drug phenytoin in neuropathic pain and fibromyalgia. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 2), MEDLINE, and EMBASE to 28 February 2012, together with reference lists of retrieved papers and reviews, and ClinicalTrials.gov. We planned to include randomised, double-blind studies of eight weeks duration or longer, comparing phenytoin with placebo or another active treatment in chronic neuropathic pain or fibromyalgia. Two review authors would independently extract data for efficacy and adverse events, and examine issues of study quality. We did not identify any studies that satisfied the inclusion criteria. This review uncovered no evidence of sufficient quality to support the use of phenytoin in chronic neuropathic pain or fibromyalgia.

MATERIALS
Product Number
Brand
Product Description

Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Supelco
Phenytoin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Phenytoin, European Pharmacopoeia (EP) Reference Standard
USP
Phenytoin, United States Pharmacopeia (USP) Reference Standard
Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard